Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Table 4 Patients with improved quality of life – EQ-5D-3 L questionnaire (longitudinal population)

Parameter	Baseline (N = 121)	6 months (N = 113)	12 months (N = 103)
No problems in walking	47.9	73.5	72.8
No problems in self-care	74.4	91.2	90.3
No problems in performing usual activities^a	36.7	58.4	65.0
No pain/discomfort^b	31.4	61.9	63.7
No anxiety/depression	34.7	57.5	57.3
VAS scores, mean ± SD	55.1 ± 18.4	69.2 ± 15.9	71.0 ± 16.0

Data are presented as % of patients, unless otherwise specified
^aN = 120 at baseline; ^bN = 102 at 12 months
P < 0.0001 for VAS score changes from baseline to 6 months as well as 12 months. P-value was calculated using paired t-test
EQ-5D-3 L EuroQoL five-dimensional three-level questionnaire, SD standard deviation, VAS Visual Analogue Scale

ISSN: 1939-4551